ArticleInternational journal of cancer2026

TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.

Christos Fountzilas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.